SOURCE: MediJane Holdings Inc.
LONGMONT, CO--(Marketwired - May 12, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that the Company has appointed Mr. Russell G. Stone as its new Chief Operating Officer (COO).
Since 2002, Mr. Stone has been a managing member and active principal of Stone Financial Group, LLC, Jo-Bar Enterprises, LLC, and Stone Brothers Capital LLC -- the business of which were created to participate in a diversified array of investment offerings that include, but are not limited to, lending, hospitality, real estate, medical, technology, and the secondary life insurance market. Mr. Stone's responsibilities within the companies include investor and broker relations, portfolio analysis, and management. Additionally, Mr. Stone is responsible for the monitoring of loans and the seeking of new investment opportunities for the family of companies.
Mr. Stone also co-founded Finiti Branding Group, LLC ("FBG") in 2011. FBG was a privately held company established to take advantage of the rapidly growing electronic cigarette industry. FIN electronic cigarettes (www.fincigs.com) can now be found in national chains such as Walgreens, AM-PM, and Walmart to name a few. FBG was acquired in 2014. Mr. Stone had many responsibilities within FBG including President, VP of Supply Chain, and VP of Business Insight. Within his role as FBG President, Mr. Stone was responsible for all aspects of FBG's business including the organizational structure, evaluating staffing needs, and driving the vision of the company. Mr. Stone was the general liaison to the various FBG department heads to ensure proper communication and coordination of information.
Throughout his career, Mr. Stone has had an entrepreneurial spirit that has led him to assist and build several startup companies. He began his career within the culinary fields in which he was involved in two restaurant openings where he held numerous positions. He currently is a founding member of a startup beverage business where he acts as a consultant and advisor to the company on its distribution, sales and merchandising, and roll out strategies.
Mr. Stone graduated from the University of Kansas in 1996 with a Bachelor of Science degree in Business Administration with a concentration in Communication Studies. In addition, he holds an associate degree from the culinary program at Kendall College in Evanston, IL.
Lewis "Spike" Humer, Chairman of MediJane Holdings Inc., commented, "As a company that is growing in a new and quickly evolving industry, it's integral that all cogs in the wheel are operationally effective. With the addition of Russell Stone as our new Chief Operating Officer, our team now has more back end knowledge and experience ranging from rapid supply chain management to complex inventory controls. Compounding his operations credentials is his vast front end experience having started and sold several successful businesses. These factors, combined with his financial services experience, make Russell Stone an ideal fit for MediJane's business strategy and the ongoing intricacies of being a publicly traded company."
About MediJane Holdings Inc. (MJMD)
MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals (www.phoenixbiopharmaceuticals.com). With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's lead products are focused and innovative non-drowsy "Daytime Pain plus CBD" oral capsule and Canna-Mist spray have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. These smokeless alternatives provide accurate dosages and are part of MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America. Any and all medically oriented statements have not been evaluated by the Food and Drug Administration.
For more information, visit www.medijane.co
Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.